LY-320,135

LY-320,135

LY-320,135 is a drug that acts as an antagonist for the cannabinoid receptor CB1. It was developed by the pharmaceutical company Eli Lilly and has been used in scientific research to study the function of the CB1 receptor, particularly in relation to the effects of other drugs that act on this receptor.

Pharmacology

LY-320,135 is a CB1 receptor antagonist, which means it blocks the action of cannabinoid drugs at the CB1 receptor. This receptor is found in various parts of the brain and is involved in a wide range of physiological processes, including appetite regulation, pain sensation, mood, and memory.

The CB1 receptor is the primary target of the psychoactive ingredient in cannabis, delta-9-tetrahydrocannabinol (THC). By blocking the action of THC and other cannabinoids at the CB1 receptor, LY-320,135 can prevent or reduce the psychoactive effects of these drugs.

Research Uses

LY-320,135 has been used in scientific research to study the function of the CB1 receptor and the effects of drugs that act on this receptor. For example, it has been used to investigate the role of the CB1 receptor in the effects of cannabinoids on appetite and food intake, as well as their effects on pain sensation and mood.

In addition, LY-320,135 has been used to study the potential therapeutic applications of CB1 receptor antagonists. For instance, it has been used in research investigating the potential use of these drugs in the treatment of obesity, as they may help to reduce appetite and food intake.

See Also

• Cannabinoid receptor
• Cannabinoid
• Eli Lilly

References

‎